CSL Behring

1020 First Avenue
King of Prussia
Pennsylvania
19406
United States

Tel: 610-878-4000
Fax: 610-878-4009

About CSL Behring

As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.

CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.

CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!

Stock Symbol: CSL

Stock Exchange: Australian Securities Exchange

An overview of the CSL Behring Fermentation Facility at Penn State

313 articles with CSL Behring

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

3/16/2018

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks

3/15/2018

Life Sciences Pennsylvania recognized CSL Behring's commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
CSL Behring Advances to Phase III Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy

12/5/2017

The study will enroll more than 17,000 patients from approximately 1,000 sites around the world to evaluate whether CSL112 reduces cardiovascular events in high-risk patients during the critical 90 days after a heart attack.
CSL and Vitaeris Announce Strategic Partnership with Option to Acquire

12/5/2017

CSL Limited and Vitaeris today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab as a therapeutic option for solid organ transplant rejection.
Lancet Neurology Publishes Results From CSL Behring Phase III Study of Hizentra to Treat Patients With Chronic Inflammatory Demyelinating Polyneuropathy

11/9/2017

The Hizentra PATH study is the largest controlled clinical study in patients with CIDP.
Data on the Preventive Effects of HAEGARDA in Subjects With Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting

10/30/2017

CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA reduced the median number of HAE attacks per month by 98 percent in subjects who had frequent attacks, from a 16-week placebo period to a 16-week treatment period.
Japan's Ministry Of Health, Labour And Welfare Approves AFSTYLA - CSL Behring's Novel Recombinant Haemophilia A Treatment

9/28/2017
CSL Behring Release: Patient Groups Sharpen Their Capabilities To Protect Access To Medicines For Treating Rare Bleeding Disorders

9/28/2017
CSL Behring Will Help Transform Biotech Education And Research With $4.92 Million Gift To Pennsylvania State University

9/19/2017
CSL Behring Announces FDA Approval Of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] For The Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) In Adults

9/15/2017
CSL Behring Joins Together With Conference Attendees To Make Donation To IPOPI

9/14/2017
CSL Behring Scoops Up This U.S. Biotech for $416 Million

8/29/2017
CSL Behring Release: HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available In The United States For Patients With Hereditary Angioedema

7/25/2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human])

7/21/2017
FDA Accepts CSL Behring's Supplemental Biologics License Application For Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

7/19/2017
CSL Behring Release: New Data Demonstrate Prophylactic Treatment With IDELVION Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B

7/12/2017
CSL Behring Release: New Findings Show AFSTYLA Provides Long-Lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Hemophilia A

7/10/2017
CSL Behring Release: FDA Approves HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), First And Only Subcutaneous Preventive Treatment For Hereditary Angioedema

6/26/2017
CSL Behring Release: Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

3/31/2017
CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

3/30/2017